Administration of zinc chelators improves survival of mice infected with Aspergillus fumigatus both in monotherapy and in combination with caspofungin

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5631-5639

  Laskaris, Paris ^a   Atrouni, Ahmad ^a   Calera, José Antonio ^b   D'Enfert, Christophe ^a,c   Munier Lehmann, Hélène ^d   Cavaillon, Jean Marc ^a   Latgé, Jean Paul ^a   Ibrahim Granet, Oumaïma ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c INRA F 75015   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; CASPOFUNGIN; CHELATING AGENT; CLIOQUINOL; CXCL1 CHEMOKINE; DIETHYLDITHIOCARBAMIC ACID; EDETIC ACID; ETHYLENEDIAMINE N,N' DIACETIC ACID; INTERLEUKIN 6; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; PENTETIC ACID; PLACEBO; UNCLASSIFIED DRUG; ZINC CHELATING AGENT; 1,10-PHENANTHROLINE; ANTIFUNGAL AGENT; ANTISERUM; ECHINOCANDIN; ETHYLAMINE; LIPOPEPTIDE; N,N,N',N'-TETRAKIS(2-PYRIDYLMETHYL)ETHANE-1,2-DIAMINE; PHENANTHROLINE DERIVATIVE; PYRIDINE DERIVATIVE; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; BIOLUMINESCENCE; CHELATION; COMBINATION DRUG THERAPY; CONIDIUM; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS GROWTH; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; WEIGHT REDUCTION; ANIMAL; ASPERGILLOSIS; BAGG ALBINO MOUSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MICROBIOLOGY; MORTALITY; PATHOGENICITY; PATHOLOGY; PNEUMONIA; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHELATING AGENTS; CLIOQUINOL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; ETHYLAMINES; IMMUNE SERA; IMMUNOCOMPROMISED HOST; LIPOPEPTIDES; MALE; MICE, INBRED BALB C; PHENANTHROLINES; PNEUMONIA; PYRIDINES; TREATMENT OUTCOME; ZINC;

EID: 84992656336     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00324-16     Document Type: Article

References (76)

1. Abad A, Fernandez-Molina JV, Bikandi J, Ramirez A, Margareto J, Sendino J, Hernando FL, Ponton J, Garaizar J, Rementeria A. 2010. What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis. Rev Iberoam Micol 27:155-182. http://dx.doi.org/10.1016/j.riam.2010.10.003.
2. Latge JP. 1999. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12:310-350.
3. Balloy V, Chignard M. 2009. The innate immune response to Aspergillus fumigatus. Microbes Infect 11:919-927. http://dx.doi.org/10.1016/j.micinf.2009.07.002.
4. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL. 2012. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 65:453-464. http://dx.doi.org/10.1016/j.jinf.2012.08.003.
5. Patterson KC, Strek ME. 2014. Diagnosis and treatment of pulmonary aspergillosis syndromes. Chest 146:1358-1368. http://dx.doi.org/10.1378/chest.14-0917.
6. Schrettl M, Haas H. 2011. Iron homeostasis - Achilles' heel of Aspergillus fumigatus? Curr Opin Microbiol 14:400-405. http://dx.doi.org/10.1016/j.mib.2011.06.002.
7. Vicentefranqueira R, Moreno MA, Leal F, Calera JA. 2005. The zrfA and zrfB genes of Aspergillus fumigatus encode the zinc transporter proteins of a zinc uptake system induced in an acid, zinc-depleted environment. Eukaryot Cell 4:837-848. http://dx.doi.org/10.1128/EC.4.5.837-848.2005.
8. Amich J, Vicentefranqueira R, Mellado E, Ruiz-Carmuega A, Leal F, Calera JA. 2014. The ZrfC alkaline zinc transporter is required for Aspergillus fumigatus virulence and its growth in the presence of the Zn/Mn-chelating protein calprotectin. Cell Microbiol 16:548-564. http://dx.doi.org/10.1111/cmi.12238.
9. Amich J, Vicentefranqueira R, Leal F, Calera JA. 2010. Aspergillus fumigatus survival in alkaline and extreme zinc-limiting environments relies on the induction of a zinc homeostasis system encoded by the zrfC and aspf2 genes. Eukaryot Cell 9:424-437. http://dx.doi.org/10.1128/EC.00348-09.
10. Moreno MA, Ibrahim-Granet O, Vicentefranqueira R, Amich J, Ave P, Leal F, Latge JP, Calera JA. 2007. The regulation of zinc homeostasis by the ZafA transcriptional activator is essential for Aspergillus fumigatus virulence. Mol Microbiol 64:1182-1197. http://dx.doi.org/10.1111/j.1365-2958.2007.05726.x.
11. Vicentefranqueira R, Amich J, Laskaris P, Ibrahim-Granet O, Latge JP, Toledo H, Leal F, Calera JA. 2015. Targeting zinc homeostasis to combat Aspergillus fumigatus infections. Front Microbiol 6:160. http://dx.doi.org/10.3389/fmicb.2015.00160.
12. Ruhil S, Kumar V, Balhara M, Malik M, Dhankhar S, Kumar M, Kumar Chhillar A. 2014. In vitro evaluation of combination of polyenes with EDTA against Aspergillus spp. by different methods (FICI and CI Model). J Appl Microbiol 117:643-653. http://dx.doi.org/10.1111/jam.12576.
13. Clark HL, Jhingran A, Sun Y, Vareechon C, de Jesus Carrion S, Skaar EP, Chazin WJ, Calera JA, Hohl TM, Pearlman E. 2016. Zinc and manganese chelation by neutrophil S100A8/A9 (calprotectin) limits extracellular Aspergillus fumigatus hyphal growth and corneal infection. J Immunol 196:336-344. http://dx.doi.org/10.4049/jimmunol.1502037.
14. Mao X, Schimmer AD. 2008. The toxicology of Clioquinol. Toxicol Lett 182:1-6. http://dx.doi.org/10.1016/j.toxlet.2008.08.015.
15. Priel T, Aricha-Tamir B, Sekler I. 2007. Clioquinol attenuates zinc-dependent beta-cell death and the onset of insulitis and hyperglycemia associated with experimental type I diabetes in mice. Eur J Pharmacol 565:232-239. http://dx.doi.org/10.1016/j.ejphar.2007.02.064.
16. Takeda A. 2012. Zinc signaling in the hippocampus and its relation to pathogenesis of depression. J Trace Elem Med Biol 26:80-84. http://dx.doi.org/10.1016/j.jtemb.2012.03.016.
17. Oyama TM, Ishida S, Okano Y, Seo H, Oyama Y. 2012. Clioquinolinduced increase and decrease in the intracellular Zn2+ level in rat thymocytes. Life Sci 91:1216-1220. http://dx.doi.org/10.1016/j.lfs.2012.09.014.
18. Kim JH, Jang BG, Choi BY, Kwon LM, Sohn M, Song HK, Suh SW. 2012. Zinc chelation reduces hippocampal neurogenesis after pilocarpine-induced seizure. PLoS One 7:e48543. http://dx.doi.org/10.1371/journal.pone.0048543.
19. Takeda A, Iida M, Ando M, Nakamura M, Tamano H, Oku N. 2013. Enhanced susceptibility to spontaneous seizures of noda epileptic rats by loss of synaptic zn(2+). PLoS One 8:e71372. http://dx.doi.org/10.1371/journal.pone.0071372.
20. Smidt K, Jessen N, Petersen AB, Larsen A, Magnusson N, Jeppesen JB, Stoltenberg M, Culvenor JG, Tsatsanis A, Brock B, Schmitz O, Wogensen L, Bush AI, Rungby J. 2009. SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress. PLoS One 4:e5684. http://dx.doi.org/10.1371/journal.pone.0005684.
21. Siapich SA, Wrubel H, Albanna W, Alnawaiseh M, Hescheler J, Weiergraber M, Luke M, Schneider T. 2010. Effect of ZnCl2 and chelation of zinc ions by N,N-diethyldithiocarbamate (DEDTC) on the ERG b-wave amplitude from the isolated superfused vertebrate retina. Curr Eye Res 35:322-334. http://dx.doi.org/10.3109/02713680903509410.
22. O'Dell BL, Browning JD. 2013. Zinc deficiency induced in Swiss 3T3 cells by a low-zinc medium impairs calcium entry and two mechanisms of entry are involved. Biol Trace Elem Res 152:98-104. http://dx.doi.org/10.1007/s12011-012-9591-6.
23. Cho YE, Lomeda RA, Ryu SH, Lee JH, Beattie JH, Kwun IS. 2007. Cellular Zn depletion by metal ion chelators (TPEN, DTPA and chelex resin) and its application to osteoblastic MC3T3-E1 cells. Nutr Res Pract 1:29-35. http://dx.doi.org/10.4162/nrp.2007.1.1.29.
24. Krezel A, Maret W. 2006. Zinc-buffering capacity of a eukaryotic cell at physiological pZn. J Biol Inorg Chem 11:1049-1062. http://dx.doi.org/10.1007/s00775-006-0150-5.
25. Lulloff SJ, Hahn BL, Sohnle PG. 2004. Fungal susceptibility to zinc deprivation. J Lab Clin Med 144:208-214. http://dx.doi.org/10.1016/j.lab.2004.07.007.
26. Kim BJ, Kim YH, Kim S, Kim JW, Koh JY, Oh SH, Lee MK, Kim KW, Lee MS. 2000. Zinc as a paracrine effector in pancreatic islet cell death. Diabetes 49:367-372. http://dx.doi.org/10.2337/diabetes.49.3.367.
27. Yang Y, Kawataki T, Fukui K, Koike T. 2007. Cellular Zn2+ chelators cause "dying-back" neurite degeneration associated with energy impairment. J Neurosci Res 85:2844-2855. http://dx.doi.org/10.1002/jnr.21411.
28. Silva BA, Pinto MR, Soares RM, Barreto-Bergter E, Santos AL. 2006. Pseudallescheria boydii releases metallopeptidases capable of cleaving several proteinaceous compounds. Res Microbiol 157:425-432. http://dx.doi.org/10.1016/j.resmic.2005.11.010.
29. Kiss Z. 1994. The zinc chelator 1,10-phenanthroline enhances the stimulatory effects of protein kinase C activators and staurosporine, but not sphingosine and H2O2, on phospholipase D activity in NIH 3T3 fibroblasts. Biochem J 298:93-98. http://dx.doi.org/10.1042/bj2980093.
30. Chang CH, Yarbro JW, Mann DE, Jr, Gautieri RF. 1978. Effects of 1,10-phenanthroline and a zinc complex of 1,10-phenanthroline on nucleic acid synthesis in mouse liver and spleen. J Pharmacol Exp Ther 205:27-32.
31. Medina C, Videla S, Radomski A, Radomski M, Antolin M, Guarner F, Vilaseca J, Salas A, Malagelada JR. 2001. Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 36:1314-1319. http://dx.doi.org/10.1080/003655201317097182.
32. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. 2007. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 21:217-222.
33. Cho E, Hwang JJ, Han SH, Chung SJ, Koh JY, Lee JY. 2010. Endogenous zinc mediates apoptotic programmed cell death in the developing brain. Neurotox Res 17:156-166. http://dx.doi.org/10.1007/s12640-009-9085-2.
34. Galiger C, Brock M, Jouvion G, Savers A, Parlato M, Ibrahim-Granet O. 2013. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. Antimicrob Agents Chemother 57:3046-3059. http://dx.doi.org/10.1128/AAC.01660-12.
35. Lamarre C, Ibrahim-Granet O, Du C, Calderone R, Latge JP. 2007. Characterization of the SKN7 ortholog of Aspergillus fumigatus. Fungal Genet Biol 44:682-690. http://dx.doi.org/10.1016/j.fgb.2007.01.009.
36. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly PJ, Verweij PE. 2001. Comparison of spectrophotometric and visual readings of NC-CLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 39:4256-4263. http://dx.doi.org/10.1128/JCM.39.12.4256-4263.2001.
37. EUCAST. 2003. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect 9:i-viii. http://dx.doi.org/10.1046/j.1469-0691.2003.00789.x.
38. EUCAST. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 14:982-984. http://dx.doi.org/10.1111/j.1469-0691.2008.02086.x.
39. Zhang M, Su X, Sun WK, Chen F, Xu XY, Shi Y. 2014. Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species. Mycopathologia 177:11-18. http://dx.doi.org/10.1007/s11046-013-9719-z.
40. Mayr A, Aigner M, Lass-Florl C. 2012. Caspofungin: when and how? The microbiologist's view. Mycoses 55:27-35. http://dx.doi.org/10.1111/j.1439-0507.2011.02039.x.
41. Chemwatch. 2008. 1,10-Phenanthroline material safety data sheet. Santa Cruz Biotechnology, Santa Cruz, CA. http://datasheets.scbt.com/sds/AGHS/EN/sc-255888.pdf.
42. Adler M, Dinterman RE, Wannemacher RW. 1997. Protection by the heavy metal chelator N,N,N′,N′-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 35:1089-1100. http://dx.doi.org/10.1016/S0041-0101(96)00215-2.
43. Brock M, Jouvion G, Droin-Bergere S, Dussurget O, Nicola MA, Ibrahim-Granet O. 2008. Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis. Appl Environ Microbiol 74:7023-7035. http://dx.doi.org/10.1128/AEM.01288-08.
44. Granato MQ, Massapust Pde A, Rozental S, Alviano CS, dos Santos AL, Kneipp LF. 2015. 1,10-Phenanthroline inhibits the metallopeptidase secreted by Phialophora verrucosa and modulates its growth, morphology and differentiation. Mycopathologia 179:231-242. http://dx.doi.org/10.1007/s11046-014-9832-7.
45. Martin MV, Yates J, Hitchcock CA. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 41:13-16.
46. Hyun HJ, Sohn JH, Ha DW, Ahn YH, Koh JY, Yoon YH. 2001. Depletion of intracellular zinc and copper with TPEN results in apoptosis of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 42:460-465.
47. Barkalifa R, Hershfinkel M, Friedman JE, Kozak A, Sekler I. 2009. The lipophilic zinc chelator DP-b99 prevents zinc induced neuronal death. Eur J Pharmacol 618:15-21. http://dx.doi.org/10.1016/j.ejphar.2009.07.019.
48. Schneider Rde O, Fogaca Nde S, Kmetzsch L, Schrank A, Vainstein MH, Staats CC. 2012. Zap1 regulates zinc homeostasis and modulates virulence in Cryptococcus gattii. PLoS One 7:e43773. http://dx.doi.org/10.1371/journal.pone.0043773.
49. Parente AFA, De Rezende TCV, De Castro KP, Bailao AM, Parente JA, Borges CL, Silva LP, Soares CMD. 2013. A proteomic view of the response of Paracoccidioides yeast cells to zinc deprivation. Fungal Biol 117:399-410. http://dx.doi.org/10.1016/j.funbio.2013.04.004.
50. Hood MI, Mortensen BL, Moore JL, Zhang Y, Kehl-Fie TE, Sugitani N, Chazin WJ, Caprioli RM, Skaar EP. 2012. Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog 8:e1003068. http://dx.doi.org/10.1371/journal.ppat.1003068.
51. Ibrahim-Granet O, Jouvion G, Hohl TM, Droin-Bergere S, Philippart F, Kim OY, Adib-Conquy M, Schwendener R, Cavaillon JM, Brock M. 2010. In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiol 10:105. http://dx.doi.org/10.1186/1471-2180-10-105.
52. Grahl N, Cramer RA, Jr. 2010. Regulation of hypoxia adaptation: an overlooked virulence attribute of pathogenic fungi? Med Mycol 48:1-15. http://dx.doi.org/10.3109/13693780902947342.
53. Wezensky SJ, Cramer RA, Jr. 2011. Implications of hypoxic microenvironments during invasive aspergillosis. Med Mycol 49(Suppl 1):S120-S124. http://dx.doi.org/10.3109/13693786.2010.495139.
54. Blatzer M, Barker BM, Willger SD, Beckmann N, Blosser SJ, Cornish EJ, Mazurie A, Grahl N, Haas H, Cramer RA. 2011. SREBP coordinates iron and ergosterol homeostasis to mediate triazole drug and hypoxia responses in the human fungal pathogen Aspergillus fumigatus. PLoS Genet 7:e1002374. http://dx.doi.org/10.1371/journal.pgen.1002374.
55. Elefanti A, Mouton JW, Krompa K, Al-Saigh R, Verweij PE, Zerva L, Meletiadis J. 2013. Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob Agents Chemother 57:1625-1631.
56. Prigitano A, Esposto MC, Tortorano AM. 2014. Comparison of effects of human serum and horse serum on in vitro susceptibility testing of echinocandins. J Chemother 26:62-63. http://dx.doi.org/10.1179/1973947813Y.0000000086.
57. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 51:4214-4216. http://dx.doi.org/10.1128/AAC.01589-06.
58. Even MS, Sandusky CB, Barnard ND. 2006. Serum-free hybridoma culture: ethical, scientific and safety considerations. Trends Biotechnol 24:105-108. http://dx.doi.org/10.1016/j.tibtech.2006.01.001.
59. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. 2005. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353:38-52. http://dx.doi.org/10.1016/j.jmb.2005.07.075.
60. Hobara N, Taketa K. 1976. Electrophoretic studies of clioquinol binding to human serum proteins. Biochem Pharmacol 25:1601-1606. http://dx.doi.org/10.1016/0006-2952(76)90470-6.
61. Ibrahim AS, Edwards JE, Jr, Fu Y, Spellberg B. 2006. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 58:1070-1073. http://dx.doi.org/10.1093/jac/dkl350.
62. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE, Jr, Spellberg BJ. 2007. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117:2649-2657. http://dx.doi.org/10.1172/JCI32338.
63. Ibrahim AS, Gebremariam T, French SW, Edwards JE, Jr, Spellberg B. 2010. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother 65:289-292. http://dx.doi.org/10.1093/jac/dkp426.
64. Ibrahim AS, Gebremariam T, Luo G, Fu Y, French SW, Edwards JE, Jr, Spellberg B. 2011. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother 55:1768-1770. http://dx.doi.org/10.1128/AAC.01577-10.
65. Reed C, Ibrahim A, Edwards JE, Jr, Walot I, Spellberg B. 2006. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 50:3968-3969. http://dx.doi.org/10.1128/AAC.01065-06.
66. Busca A, Marmont F, Locatelli F, Limerutti G, Sorrentino MT, Barbui A, Patrono D, Salizzoni M, David E, De Rosa F. 2010. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses 53:275-278. http://dx.doi.org/10.1111/j.1439-0507.2009.01708.x.
67. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, Walsh TJ, Ibrahim AS. 2009. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 53:3122-3125. http://dx.doi.org/10.1128/AAC.00361-09.
68. Vitale RG, Afeltra J, Dannaoui E. 2005. Antifungal combinations. Methods Mol Med 118:143-152.
69. Martin-Pena A, Aguilar-Guisado M, Espigado I, Cisneros JM. 2014. Antifungal combination therapy for invasive aspergillosis. Clin Infect Dis 59:1437-1445. http://dx.doi.org/10.1093/cid/ciu581.
70. Zanette RA, Alves SH, Pilotto MB, Weiblen C, Fighera RA, Wolkmer P, Flores MM, Santurio JM. 2013. Iron chelation therapy as a treatment for Pythium insidiosum in an animal model. J Antimicrob Chemother 68:1144-1147. http://dx.doi.org/10.1093/jac/dks534.
71. Panackal AA, Parisini E, Proschan M. 2014. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis 28:80-94. http://dx.doi.org/10.1016/j.ijid.2014.07.007.
72. Steinbach WJ, Stevens DA. 2003. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37(Suppl 3):S157-S187. http://dx.doi.org/10.1086/376523.
73. Deresinski SC, Stevens DA. 2003. Caspofungin. Clin Infect Dis 36:1445-1457. http://dx.doi.org/10.1086/375080.
74. Heinz WJ, Einsele H. 2008. Caspofungin for treatment of invasive aspergillus infections. Mycoses 51(Suppl 1):S47-S57.
75. Zarember KA, Cruz AR, Huang CY, Gallin JI. 2009. Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antimicrob Agents Chemother 53:2654-2656. http://dx.doi.org/10.1128/AAC.01547-08.
76. Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti MC, Grohmann U, Segal BH, Puccetti P. 2008. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451:211-215. http://dx.doi.org/10.1038/nature06471.